APLS - DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit | Benzinga
SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Apellis class action lawsuit, captioned Soderberg v. Apellis Pharmaceuticals, Inc., No. 23-cv-00834 (D. Del.), charges Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) along with certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Apellis class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-apellis-pharmaceuticals-inc-class-action-lawsuit-apls.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the Apellis class action lawsuit must be filed with the court no later than October 2, 2023.
CASE ALLEGATIONS: One of Apellis' leading therapeutic treatments, "SYFOVRE," is an intravitreal pegcetacoplan injection that is the first and only approved therapy for geographic atrophy, a leading cause of blindness. The Apellis class action lawsuit alleges that on January 28, 2021, Apellis published an online presentation to shareholders titled "Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA)," which highlighted its ongoing Phase 3 "DERBY and OAKS" clinical trials and its completed Phase 2 "FILLY" clinical trial. The Apellis class action lawsuit further alleges in its presentation to shareholders, Apellis touted the efficacy of using pegcetacoplan in patients with GA, including that the Phase 2 FILLY trial showed decreased lesion growth and that safety was "in line with other studies of intravitreally administered agents."
The Apellis class action lawsuit alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients ...